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NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)—Clinical Outcomes Studies
PNL1
HOW COGNITIVE FUNCTION AFFECTS ACTIVITIES OF DAILY
LIVING IN PATIENTS WITH ALZHEIMER’S DISEASE
Treglia M1, Bushmakin A2, Siddiqi S2, Cappelleri JC1
1Pﬁzer Inc, Groton, CT, USA; 2Pﬁzer Global Research and
Development, Groton, CT, USA
OBJECTIVES: To attach meaningfulness to clinically relevant
differences on cognitive functioning using activities of daily
living. METHODS: Baseline data from a 12-week clinical trial
of patients with mild-to-moderate Alzheimer’s disease (n = 212).
Logistic regressions were used to examine the effect of the Mini
Mental State Exam (MMSE) and, separately, the Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-cog) on the
Alzheimer’s Disease Cooperative Study-Activity of Daily Living
Inventory (ADCS-ADLI), after controlling for age and gender. A
3-point improvement on each of the two measures of cognitive
function (MMSE and ADAS-cog) was taken a priori to be a clin-
ically relevant difference between patients. Under that deﬁnition,
an odds ratio (OR) of successfully performing each of 49 differ-
ent activities of daily living was obtained. RESULTS: Subjects
had a mean age of 75 years (SD = 8; range: 50–90) and were
mostly white (92%) and female (58%). The Pearson correlation
between ADAS-Cog and MMSE scores was -0.77 (p-value <
0.01). A statistically signiﬁcant association (p-value < 0.05)
existed between ADAS-Cog and 24 ADCS-ADLI items, and
between MMSE and 22 ADCS-ADLI items. For these items, esti-
mated odd ratios of performing an activity of daily living were
1.15 to 1.49 times more likely for every 3-point improvement in
ADAS-Cog, and 1.3 to 2.3 times more likely for every 3-point
improvement in MMSE. A 3-point improvement in ADAS-Cog
(MMSE) reﬂected an average increase of 27% (62%) in the odds
of performing activities of daily living. CONCLUSION: Linking
clinically relevant differences on two common measures of cog-
nitive functioning (MMSE and ADAS-cog) to activities of daily
living can enhance the interpretation of these measures.
PNL2
OXCARBAZEPINE REDUCES HOSPITALISATIONS FOR
EPILEPTIC SEIZURES AND RELATED SYMPTOMS IN THE
NETHERLANDS: A PHARMO STUDY
Erkens JA1, Panneman MJ1, Snyder EH2, Herings RMC1
1PHARMO Institute, Utrecht,The Netherlands; 2Novartis
Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: The purpose of this study is to investigate the
incidence of hospitalisations for epileptic seizures and related
events before and after the start of therapy with oxcarbazepine.
METHODS: All patients using oxcarbazepine or any other anti-
epileptic drug are selected (Jan 1991–Jan 2001) from the
PHARMO Record Linkage System, a patient-centric database
including complete histories of drug use and hospitalisations for
more than 1.6 million residents in The Netherlands. Information
collected included diagnosis, drug type and daily dosage, legend
duration of use, drug costs, reasons for hospital admission and
discharge, and resources used during hospital stay. Patients had
to have at least 1 year of data before and after their ﬁrst oxcar-
bazepine prescription (index date), and had to have been on
oxcarbazepine therapy for at least one year. Poisson regression
analysis was applied to estimate the incidence density rates 
as proxy for the relative risk of hospitalisation while on and 
off therapy with oxcarbazepine. RESULTS: This study included
360 patients using oxcarbazepine and show that the incidence
rate of hospitalisations for epileptic seizures and related events
decreased signiﬁcantly during the ﬁrst year after the start of
oxcarbazepine compared to the 1-year period before the start of
treatment with oxcarbazepine. During the year prior to receiv-
ing oxcarbazepine therapy, 117 hospitalisations per 1000 person
years (n = 41) were observed in the study patients compared with
40 hospitalisations per 1000 person years (n = 11) after initiat-
ing oxcarbazepine therapy, yielding a relative risk of 0.3 (95%
CI: 0.2–0.7). CONCLUSIONS: Treatment with oxcarbaze-
pine signiﬁcantly reduces the occurrence of epilepsy-related 
hospitalizations.
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
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NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
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PREDICTORS OF LOST PRODUCTIVITY AMONG EMPLOYEES
WITH MIGRAINE HEADACHES IN A MEDICAL GROUP
SETTING: IMPLICATIONS FOR WORKSITE DISEASE
MANAGEMENT PROGRAMS
Borok G1, Ershoff D2, Maurer R3,Webb D3, Pesa J4
1AstraZeneca, Encino, CA, USA; 2AstraZeneca,Tarzana, CA, USA;
3St. Joseph Heritage Health care, La Mirada, CA, USA; 4AstraZeneca,
Wilmington, DE, USA
OBJECTIVE: Determine predictors of reduced productivity
(absenteeism and presenteeism) among employees experiencing
migraines. METHODS: Seven hundred twelve Health Risk
Assessment surveys were distributed to health care workers in a
large, multispecialty medical group in Southern California; 455
returned (64% response rate). One hundred eighty met IHS
migraine criteria (deﬁned by severity and frequency of symp-
toms). Respondents were 92% female; mean age of 37.
Migraineurs were asked about absenteeism (full and partial days
missed due to headache) and presenteeism (days worked with
headache and self-reported productivity with headache) over the
most recent 4-week period. RESULTS: A total of 68.3% (n =
123) of migraineurs reported some level of productivity loss,
with a mean of 14.2 hours. A hierarchical stepwise multiple
regression was conducted to identify signiﬁcant predictors of
productivity loss. With frequency and severity of migraines, and
use of triptans and prescription pain medication blocked into the
equation on the ﬁrst step (R2 of 23%) as clinical predictors, self-
care activities (maintain regular sleep cycle, eat regularly, control
diet to avoid triggers) and employee conﬁdence in ability to
control headaches (as employee predictors) added R2 of 9.6%,
for a total R2 of 32.6% in productivity loss. As contrasted with
employees reporting low conﬁdence in ability to control
headaches, their counterparts with high conﬁdence had 11.6
fewer hours of lost productivity (P < 0.05). Employees actively
engaged in self-care management activities (vs. not) experienced
5.3 fewer hours of lost productivity (P < 0.05). Among employee
subgroup (n = 41) under current professional treatment for
headaches, those satisﬁed with the provider’s skill in helping
them gain control of headache symptoms were signiﬁcantly less
likely to experience reduced productivity versus their dissatisﬁed
counterparts (12.3 versus 23.3 hours, P < 0.10). CONCLU-
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SION: The results of this employee survey demonstrate that
beyond migraine severity and medication therapy, there are
potentially modiﬁable employee and provider factors, which sig-
niﬁcantly reduce lost productivity associated with migraines.
PNL4
IMPACT OF MIGRAINE AND NON-MIGRAINE HEADACHES ON
EMPLOYEE PRODUCTIVITY IN A MEDICAL GROUP SETTING
Maurer R1, Borok G2, Ershoff D3,Webb D1, Ross T4
1St. Joseph Heritage Health care, La Mirada, CA, USA; 2AstraZeneca,
Encino, CA, USA; 3AstraZeneca,Tarzana, CA, USA; 4AstraZeneca,
Newport Beach, CA, USA
OBJECTIVES: Determine prevalence of employees (via self-
report) experiencing migraine (MID) and non-migraine (NMIG)
headaches; and extent of reduced productivity (absenteeism and
presenteeism) in MIG and NMIG groups. METHODS: A total
of 712 Health Risk Assessments were distributed to health care
workers in a large, multispecialty medical group in Southern Cal-
ifornia; 455 returned (64% response rate). Respondents were
87% female; mean age of 45. Responders classiﬁed into no
headache, migraine (deﬁned by severity and frequency of symp-
toms using IHS criteria), and non-migraine. Headache sufferers
were asked about absenteeism (full and partial days missed due
to headache) and presenteeism (days worked with headache and
self-reported productivity with headache) over the most recent 4
week period. RESULTS: Twenty-ﬁve percent reported having no
headaches in past 6 months, 35% had non-migraine headaches,
and 40% had migraines. Combining absenteeism and presen-
teeism, 68.3% MIG and 44.7% NMIG sufferers reported pro-
ductivity loss due to headaches in the prior 4 week period. MIG
sufferers reported a mean of 9.72 hours of lost productivity, of
which 8.13 hours were due to presenteeism. NMIG employees
reported a mean of 3.94 hours of lost productivity, of which 3.37
were due to presenteeism. On annualized basis, employees with
migraines lost total of 15.85 days: 13.21 days due to presen-
teeism, 1.78 days due to full missed work days and 0.86 days
due to partial missed days. The annual cost to the medical group
for lost productivity for headache employees is $887,976 ($1247
per employee): $645,161 for MIG sufferers and $229,815 
for NMIG employees. CONCLUSIONS: The results of this
employee survey demonstrate that migraine headaches are both
a prevalent and expensive condition for an employer. The mag-
nitude of the cost is surprisingly large in a health care organiza-
tion with employees who would be assumed to be fairly
sophisticated and have ready access to physicians for diagnosis
and treatment.
PNL5
COST-EFFECTIVENESS ANALYSIS OF RIZATRIPTAN AND
SUMATRIPTAN VERSUS CAFERGOT IN THE ACUTE
TREATMENT OF MIGRAINE
Zhang L1, Hay JW2
1University of Southern California, Los Angeles, CA, USA; 2USC
School of Pharmacy, Los Angeles, CA, USA
Both ergotamine and tritpans are currently used in the treatment
of acute migraine. Ergotamine is a traditional therapy with lower
drug acquisition cost and less headache recurrence. It has been
showed that tritpans are more efﬁcacious than ergotamine. But
their high acquisition costs and the short duration of action
remain as their major disadvantages. OBJECTIVE: The purpose
of this study is to provide a comparison of cost-effectiveness of
rizatriptan and sumatritpan with Cafergot in the treatment of
acute migraine attack. METHODS: Three separate models were
developed based on a decision tree (Model 1: rizatriptan 
vs. Cafergot; Model 2: sumatritpan vs. Cafergot; Model 3: 
rizatritpan vs. sumatritpan). Time horizon was one year. Cost-
effectiveness analysis was conducted from the societal perspec-
tive using data from the literature. All costs were converted to
year 2003 dollars. The CE ratio was expressed in incremental
cost/incremental QALYs. RESULTS: Base case evaluation
showed that both rizatriptan and sumatriptan dominated 
Cafergot (provide the cost differences and QALY differences for
the different Meds). Sensitivity analysis showed that the CE
ratios were sensitive to moderate changes in effectiveness of trip-
tans. The study further showed that rizatritpan is more cost-
effective than sumatriptan, as evidenced by the negative CE ratio.
Cost-effective ratios are not sensitive to changes of key variables,
which include efﬁcacy, utility, drug costs, hospitalization cost
and patient preference over alternative therapies. CONCLU-
SION: Rizatriptan and sumatritpan are both more cost-effective
than Cafergot in the treatment of acute migraine attack. Riza-
tritpan also dominated sumatritpan. Additional quality of life
studies are needed to conﬁrm the beneﬁt from using triptans in
management of migraine.
PNL6
COMPARISON OF CLINICAL EFFICACY AND COST-
EFFECTIVENESS BETWEEN ELETRIPTAN 40 MG AND
SUMATRIPTAN 100 MG IN THE ACUTE TREATMENT 
OF MIGRAINE
Healey PJ, Dugar A,Weis K
Pﬁzer Global Pharmaceuticals, Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The objectives of this study were to compare the
clinical efﬁcacy and cost-effectiveness of eletriptan 40mg vs.
sumatriptan 100mg for the acute treatment of migraine attack.
METHODS: Data were extracted and pooled from three ran-
domized head-to-head clinical trials comparing the efﬁcacy of
eletriptan 40mg and sumatriptan 100mg. Three composite mea-
sures of treatment success were used based on sustained response
(no recurrence of moderate to severe headache or use of rescue
medication from the stated time period to 24 hours post-dose):
1-hour sustained response, with improvement of headache pain
from moderate to severe at baseline to mild or absent within 1
hour; 2-hour sustained response, with improvement to absent or
mild pain within 2 hours post-dose; and 2-hour sustained pain-
free, with improvement to pain-free within 2 hours. The cost per
successfully treated patient (CPSTP) was calculated for each
outcome based on the wholesale acquisition cost (WAC) for 
each medication (AnalySource®, September 2003). The 95%
conﬁdence interval (CI) was calculated using bootstrapping 
technique. RESULTS: Eletriptan 40mg was superior to suma-
triptan 100mg across each of the three outcomes: 1-hour sus-
tained, 20% vs. 15% (P < 0.01); 2-hour sustained, 41% vs. 34%
(P < 0.001); and 2-hour sustained pain-free, 22% vs. 15% 
(P < 0.0001). The CPSTP was lower for eletriptan than suma-
triptan for all three measures: 1-hour sustained response, $81 
vs. $129; 2-hour sustained, $40 vs. $57; 2-hour sustained pain-
free, $74 vs. $133. CONCLUSIONS: Eletriptan 40mg had 
consistently greater positive clinical impact than sumatrip-
tan 100mg in the acute treatment of migraine. The greater 
efﬁcacy and lower recurrence rate also translated into better 
cost-effectiveness.
PNL7
A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT
COSTS OF MIGRAINE AND ITS COMORBID CONDITIONS 
IN TAIWAN
Lin CW, Lee CT
Bureau of National Health Insurance, Kao-Ping Branch, Kaohsiung
City,Taiwan
